# Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

> **NCT04072237** · PHASE1 · COMPLETED · sponsor: **Catalyst Biosciences** · enrollment: 11 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B
- Hemophilia A With Inhibitor
- Hemophilia B With Inhibitor
- Hemophilia A Without Inhibitor
- Hemophilia B Without Inhibitor

## Interventions

- **BIOLOGICAL:** MarzAA (marzeptacog alfa [activated])

## Key facts

- **NCT ID:** NCT04072237
- **Lead sponsor:** Catalyst Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-06-17
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072237, "Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04072237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*